Medpace Holdings, Inc. $MEDP Shares Purchased by Algert Global LLC

Algert Global LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,809 shares of the company’s stock after buying an additional 2,429 shares during the period. Algert Global LLC owned approximately 0.15% of Medpace worth $21,497,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Quent Capital LLC acquired a new stake in Medpace in the third quarter valued at about $25,000. Optiver Holding B.V. purchased a new stake in Medpace in the 3rd quarter valued at approximately $27,000. Root Financial Partners LLC acquired a new position in Medpace during the 3rd quarter worth approximately $38,000. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Finally, Ameriflex Group Inc. raised its stake in shares of Medpace by 100.0% during the 3rd quarter. Ameriflex Group Inc. now owns 100 shares of the company’s stock worth $51,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.5%

Shares of MEDP stock opened at $450.41 on Friday. The stock has a market cap of $12.78 billion, a P/E ratio of 29.44, a P/E/G ratio of 2.16 and a beta of 1.44. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The business has a fifty day simple moving average of $523.62 and a 200-day simple moving average of $538.95.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and decreased their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Mizuho set a $582.00 price objective on Medpace in a research report on Wednesday, February 11th. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price for the company in a report on Friday, March 6th. Leerink Partners decreased their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada assumed coverage on shares of Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.